Peiying Ji

Dr. Peiying Ji


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2024 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
AZAole Zheng
Aole Zheng
Dongsheng YangDongsheng Yang
Dongsheng Yang
CPChunyang Pan
Chunyang Pan
QHQingfeng He
Qingfeng He
XZXiao Zhu
Xiao Zhu
PJPeiying Ji
Peiying Ji
Lenvatinib's efficacy as a frontline targeted therapy for radioactive iodine-refractory thyroid carcinoma and advanced hepatocellular carcinoma owes to its inhibition of multiple tyrosine kinases. However, as a CYP3A4 substrate, lenvatinib bears susceptibility to pharmacokinetic modulation by co-administered agents. Schisantherin A (STA) and schisandrin A (SIA) - bioactive lignans abundant in the traditional Chinese medicinal Wuzhi Capsule - act as CYP3A4 inhibitors, engendering the potential for drug-drug interactions (DDIs) with lenvatinib. To explore potential DDIs between lenvatinib and STA/SIA, we developed a physiologically-based pharmacokinetic (PBPK) model for lenvatinib and used it to construct a DDI model for lenvatinib and STA/SIA. The model was validated with clinical trial data and used to predict changes in lenvatinib exposure with combined treatment. Following single-dose administration, the predicted area under the plasma concentration-time curve (AUC) and maximum plasma concentrations (Cmax) of lenvatinib increased 1.00- to 1.03-fold and 1.00- to 1.01-fold, respectively, in the presence of STA/SIA. Simulations of multiple-dose regimens revealed slightly greater interactions, with lenvatinib AUC0-t and Cmax increasing up to 1.09-fold and 1.02-fold, respectively. Our study developed the first PBPK and DDI models for lenvatinib as a victim drug. STA and SIA slightly increased lenvatinib exposure in simulations, providing clinically valuable information on the safety of concurrent use. Given the minimal pharmacokinetic changes, STA/SIA are unlikely to interact with lenvatinib through pharmacokinetic alterations synergistically but rather may enhance efficacy through inherent anti-cancer efficacy of STA/ SIA.

26 May 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
BCBowen Chen
Bowen Chen
LLLongjie Li
Longjie Li
WXWenhang Xu
Wenhang Xu
HXHaiping Xu
Haiping Xu
XZXinyan Zhu
Xinyan Zhu
PJPeiying Ji
Peiying Ji
Background: Irinotecan (CPT-11) is a prodrug that is bioactivated to SN-38, which is primarily cleared via UGT1A1-mediated glucuronidation. Its complex metabolism, which also involves CYP3A-mediated oxidation, makes irinotecan highly susceptible to enzyme-mediated drug-drug interactions (DDIs). This study aimed to develop and qualify an adult whole-body physiologically based pharmacokinetic (PBPK) model of irinotecan and its metabolites (SN-38, SN-38G, and APC) to predict systemic pharmacokinetics and UGT1A1/CYP3A-mediated DDIs. Methods: An adult middle-out PBPK model was implemented in Simcyp®, integrating key pathways for carboxylesterase (CES) -mediated activation, UGT1A1/UGT1A9-driven glucuronidation, and CYP3A4/5-mediated oxidation. The model was calibrated using 175–300 mg/m 2 monotherapy data and was validated across a 33–750 mg/m 2 dose range, including drug-drug interactions with ketoconazole, sorafenib, and lopinavir/ritonavir. Results: Most observed irinotecan and SN-38 concentrations fell within the fifth–95th percentile prediction intervals, and dose–exposure slopes were close to unity. Across monotherapy evaluations, 54/56 (96.4%) comparisons of maximum concentration (C max ) and area under the concentration–time curve (AUC) met the 2-fold acceptance criterion. The model further captured the direction and magnitude of exposure changes across all inhibitor scenarios, with CPT-11 and SN-38 exposure ratios remaining within acceptable limits, although APC exposure was overpredicted in the ketoconazole scenario. Conclusion: The mechanistically informed and validated whole-body PBPK model reliably describes dose-dependent irinotecan and SN-38 pharmacokinetics and UGT1A1/CYP3A-mediated drug-drug interactions. This framework provides a clinically relevant tool for enzyme-mediated DDI risk assessment and for exploratory simulation of dose–exposure relationships under standard irinotecan regimens.